The Halozyme Therapeutics Inc (HALO) share price is expected to increase by 33.33% over the next year. This is based on calculating the average 12-month share price estimate provided by 9 stock analysts who have covered HALO. Price targets range from $28.00 at the low end to $72.00 at the high end. The current analyst consensus for HALO is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 9 Wall Street analysts have assigned HALO 6 buy ratings, 2 hold ratings, and 1 sell ratings. This means that analysts expect Halozyme Therapeutics Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on HALO. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
jason butler JMP Securities | Buy | $72.0 | reiterated | Feb 14, 2024 |
robert wasserman Benchmark Co. | Buy | $50.0 | maintained | Feb 13, 2024 |
mitchell kapoor H.C. Wainwright | Buy | $48.0 | reiterated | Jan 19, 2024 |
corinne jenkins Goldman Sachs | Hold | $40.0 | maintained | Jan 18, 2024 |
david risinger Leerink Partners | Hold | $37.0 | maintained | Jan 17, 2024 |
eun yang Jefferies | Sell | $28.0 | maintained | Jan 17, 2024 |
joseph catanzaro Piper Sandler | Buy | $46.0 | maintained | Jan 5, 2024 |
mohit bansal Wells Fargo | Buy | $52.0 | maintained | Jan 4, 2024 |
vikram purohit Morgan Stanley | Buy | $59.0 | maintained | Dec 26, 2023 |
caroline palomeque Berenberg Bank | Buy | $58.0 | maintained | Sep 11, 2023 |
jessica fye J.P. Morgan | Buy | $52.0 | maintained | Feb 22, 2023 |
andrew galler Morgan Stanley | Buy | $50.0 | initiatedcoverage | Sep 9, 2022 |
vamil divan Mizuho Securities | Buy | $52.0 | initiatedcoverage | May 22, 2022 |
anita dushyanth Berenberg Bank | Buy | $56.0 | maintained | Feb 25, 2022 |
arlinda lee Canaccord Genuity | Buy | $50.0 | maintained | Jan 31, 2022 |
graig suvannavejh Mizuho Securities | Buy | $50.0 | maintained | Nov 15, 2021 |
matthew luchini BMO Capital | Buy | $62.0 | reiterated | Nov 3, 2021 |
geoff porges SVB Securities | Buy | $48.0 | rated | Nov 3, 2021 |
do kim Piper Sandler | Buy | $66.0 | maintained | Aug 10, 2021 |
michael difiore Evercore ISI | Buy | None | initiatedcoverage | Jun 14, 2021 |
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
When did it IPO
0
Staff Count
393
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
Market Cap
$4.77B
In 2023, HALO generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that HALO's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
$77.82
ONB-USD
$16.44
OZK-USD
$42.65
COOP-USD
$72.4
$34.55
COLM-USD
$81.5